Observational studyJournal of the American Heart Association2025

Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA-SRV Trial.

Mathieu Albertini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.